MANE · Veradermics, Inc
$101.34
-1.46 (-1.42%)
At close · Aug 27
Going-concern doubt
— cleared Aug 11, 2026
The latest filing no longer states the doubt (first flagged May 12, 2026).
View the 10-Q filed Aug 11, 2026Market Cap
$4.38B
Shares
41.78M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$102.80
Open$102.04
Day$101.30–104.87
Available close range$37.03–129.74
Avg vol 30d784K
Short int4.0M · 9.6% float · 4.0d
Short vol54%
Last earningsAug 11, 2026
DataFeb 2026–Aug 2026
Filing10-Q · Aug 11
The closing range uses available history since Feb 4, 2026; less than a full year is stored.
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 11, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Strong
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.2 · calm
Equity put/call 0.64
Technical
price trend
50 / 200-day cross
No cross
Price vs 50-day avg
−7%
below
RSI (14)
44
neutral
MACD trend
Negative
52-week position
71%
mid-range
Momentum
relative strength
1-month return
−5%
trailing
6-month return
+111%
trailing
Relative strength
+99%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+101% holders QoQ · +96 funds added
Insider flow
Distributing
Net -$91.1M over 90 days · 100% sells
Short interest
Falling
9.60% of float · ▼ -16.8% MoM · 4.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
163 holders — 13F breadth
Squeeze score
54
elevated · 0–100
Fundamentals
EPS growth
−202%
Y/Y
Free cash flow
$-71.6M
Balance sheet
$21.8M
net cash
Quant / Vol
risk profile
Volatility
99%
annualized · 1-yr
Max drawdown
−24%
past year
ATR
6.8%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 50-day avg
−7%
Bearish
RSI (14)
44
Neutral
MACD trend
Negative
Bearish
52-week position
71%
Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50/200-day averages unavailable
Institutional flow
Accumulating
+101% holders QoQ · +96 funds added
Insider flow
Distributing
Net -$91.1M over 90 days · 100% sells
Short interest
Falling
9.60% of float · ▼ -16.8% MoM · 4.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
163 holders — 13F breadth
Price context
position in its available closing range
Range low $37
Now $103 · 71%
Range high $130
vs 50-day avg -7%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MANE
this stock
Veradermics, Inc
|
$4.38B | — | — | — | 9.6% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.72B | +20.7% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$83.89B | +5.6% | +20.8% | 20.2 | 2.3% |
|
ARGX
Argenx SE
|
$65.12B | +24.5% | — | — | 1.9% |
|
CSLLY
Csl Ltd
|
$59.92B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MANE | -7.6% | -4.6% | +111.4% | -2.1% | — |
| SPY | -0.4% | +5.0% | +12.4% | +2.6% | +12.3% |
| vs SPY | -7.2% | -9.6% | +99.0% | -4.7% | — |
Key facts
CIK
1827635
CUSIP
922967104
13F (30d)
156 filings
154 filers
Visit website
Investor relations